Safeguarding Digital Wellness: India Strengthens Quality Oversight and Prescription Controls for Online AYUSH Products

NEW DELHI — In response to the rapid expansion of digital commerce and e-commerce platforms, the Government of India has unveiled a comprehensive regulatory and quality assurance framework designed to police traditional Indian medicine products sold online. The multi-pronged strategy establishes mandatory prescription checks for potent herbal formulations, creates digital watchdog tools, and enforces rigorous manufacturing standards for Ayurvedic, Siddha, Unani, Sowa-Rigpa, and Homoeopathic (ASSU&H) remedies.

The policy outline was presented in a written reply to the Rajya Sabha on July 21, 2026, by Union Minister of State (Independent Charge) for Ayush, Shri Prataprao Jadhav. As millions of consumers increasingly turn to online shopping for health and wellness supplements, the initiative addresses growing public health concerns surrounding unverified claims, counterfeit products, and the unregulated sale of potent herbal ingredients across digital marketplaces.

Closing the Digital Gap: Mandatory Prescriptions and E-Commerce Oversight

One of the most consequential changes in the regulatory framework directly targets e-commerce entities. Under a new advisory issued by the Central Consumer Protection Authority (CCPA), digital platforms are now required to enforce strict prescription requirements for specific traditional formulations.

Specifically, online sales of Ayurvedic, Siddha, and Unani drugs containing ingredients listed under Schedule E(1) of the Drugs Rules, 1945, will no longer be permitted as over-the-counter purchases. Schedule E(1) includes herbal and mineral substances—such as Aconitum (Vatsanabha), Strychnos nux-vomica (Kupilu), and heavy metal preparations—that possess therapeutic benefits but carry high toxicity risks if used without clinical supervision. E-commerce platforms must now verify that a consumer has uploaded a valid prescription from a registered Ayurveda, Siddha, or Unani medical practitioner before processing an order.

“This prescription barrier for Schedule E(1) substances is a vital consumer safety milestone,” said Dr. Sunita Ramanathan, an independent clinical pharmacologist and senior research fellow in health policy, who was not involved in drafting the statement. “While traditional systems offer immense benefits, ingredients classified under Schedule E(1) require exact dosing and expert evaluation. Allowing unchecked online access to potent herbal remedies posed genuine risks of organ toxicity and adverse drug interactions.”

Real-Time Monitoring and Pharmacovigilance Networks

To tackle misleading health claims and dangerous product representations online, the Ministry of Ayush has operationalized the Ayush Suraksha Portal. This digital platform enables consumers, healthcare professionals, and researchers to report suspected adverse drug reactions and deceptive online advertisements in real time.

┌────────────────────────────────────────────────────────────────────────┐
│                   AOGUSY Pharmacovigilance Network                     │
├────────────────────────────────────────────────────────────────────────┤
│  • 1 National Pharmacovigilance Co-ordination Centre (NPvCC)           │
│    (Located at All India Institute of Ayurveda, New Delhi)             │
│  • 5 Intermediary Pharmacovigilance Centres (IPvCs)                     │
│  • 97 Peripheral Pharmacovigilance Centres (PPvCs) Nationwide          │
└────────────────────────────────────────────────────────────────────────┘

The underlying surveillance structure operates through a nationwide three-tier pharmacovigilance network established under the Ayush Oushadhi Gunavatta Evam Uttpadan Samvardhan Yojana (AOGUSY) scheme. The network comprises:

• 1 National Pharmacovigilance Co-ordination Centre (NPvCC) based at the All India Institute of Ayurveda (AIIA) in New Delhi.

• 5 Intermediary Pharmacovigilance Centres (IPvCs) providing regional monitoring.

• 97 Peripheral Pharmacovigilance Centres (PPvCs) collecting field-level data across healthcare centers nationwide.

To enforce accountability, the Coordinator of the NPvCC at the All India Institute of Ayurveda has been designated as a statutory nodal officer under the Information Technology (IT) Act, 2000. This designation grants legal authority to issue formal take-down notices and warnings directly to digital intermediaries, search engines, and e-commerce platforms hosting misleading or objectionable advertisements regarding AYUSH products.

Standardizing Quality: From Local MSMEs to Global Markets

Beyond digital monitoring, the Ministry is bolstering physical quality standards across manufacturing pipelines. A specialized Ayush vertical within the Central Drugs Standard Control Organization (CDSCO)—India’s primary national drug regulatory body—now coordinates joint factory inspections with state and union territory drug inspectors.

┌────────────────────────────────────────────────────────────────────────┐
│                   Key Regulatory & Quality Metrics                     │
├────────────────────────────────────────────────────────────────────────┤
│ Compliance Framework │ Statutory Basis & Standard                     │
├──────────────────────┼─────────────────────────────────────────────────┤
│ Good Manufacturing   │ Schedule T (ASU) & Schedule M-I (Homoeopathy)   │
│ Practices (GMP)      │ under Drugs Rules, 1945                         │
├──────────────────────┼─────────────────────────────────────────────────┤
│ Laboratory Testing   │ National Accreditation Board for Testing and    │
│ Accreditation        │ Calibration Laboratories (NABL)                 │
├──────────────────────┼─────────────────────────────────────────────────┤
│ Global Export        │ WHO Certificate of Pharmaceutical Product       │
│ Certification        │ (WHO-CoPP) issued by CDSCO                      │
├──────────────────────┼─────────────────────────────────────────────────┤
│ Product Mark         │ Ayush Quality Mark via AYUSHEXCIL               │
└──────────────────────┴─────────────────────────────────────────────────┘

When drug inspectors collect samples from retail outlets or digital distribution centers that fail quality tests, mandatory statutory actions follow, including market recall and legal prosecution under the Drugs & Cosmetics Act, 1940.

To help small and medium enterprises (MSMEs) transition to higher manufacturing benchmarks, the central AOGUSY scheme provides financial and technical assistance to upgrade traditional pharmacies and Drug Testing Laboratories (DTLs) toward World Health Organization Good Manufacturing Practices (WHO-GMP) and National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditations. Furthermore, the Ayush Export Promotion Council (AYUSHEXCIL) has introduced the Ayush Quality Mark (AQM) to certify products meeting international safety and efficacy standards, enhancing global trade credibility.

Balanced Perspectives and Potential Challenges

While public health advocates have welcomed the regulatory framework, industry analysts note several logistical challenges in universal execution:

• E-Commerce Compliance Verification: Enforcing real-time prescription verification across thousands of independent third-party vendors on large online marketplaces remains technically complex.

• MSME Upgradation Costs: Upgrading legacy manufacturing units to meet WHO-GMP and NABL standards requires significant capital investment, which may strain smaller traditional pharmacies despite government subsidies.

• Regulatory Harmonies: Coordinating enforcement actions between central regulatory units like CDSCO and localized state drug control departments requires sustained administrative synergy to prevent legal loopholes.

“Creating statutory mechanisms is a powerful step forward, but long-term success depends on strict enforcement,” noted Dr. Rajesh Varma, a public health specialist focusing on regulatory compliance. “Consumers must also remain vigilant. No regulatory tool can fully replace an informed patient who verifies product credentials and consults qualified medical professionals.”

What This Means for Consumers

For individuals using or considering traditional health remedies, this updated regulatory framework offers clearer tools to make safe choices:

1. Look for Certified Quality Seals: Check product packaging for official seals such as the Ayush Premium Mark or the Ayush Quality Mark, which indicate independent third-party verification.

2. Obtain Prescriptions when Required: Never attempt to buy potent herbal formulations—especially those containing Schedule E(1) ingredients—without consulting a registered practitioner.

3. Report Misleading Claims: Use the government’s official Ayush Suraksha Portal to report any online product promising instant or scientifically unsupported “miracle cures”.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

Reference Section

Official Statements & Regulatory Documents

1. Press Information Bureau (PIB) Delhi. (2026, July 21). Digital market access and quality assurance framework for AYUSH products. Ministry of Ayush, Government of India. Press Release ID: 2287029.